name string | description string | version string | datePublished timestamp[s] | dateModified timestamp[s] | license string | publisher dict | scope string | methodology string | unverifiedNote string | disclaimer string | corrections string | changelog string | timeline list | claimChecks list | rows list |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Peptide Compounding Status Index | A sourced reference of the seven peptides the FDA Pharmacy Compounding Advisory Committee (PCAC) evaluated on July 23-24, 2026 for possible inclusion on the Section 503A bulk drug substances list, with each peptide's regulatory status, evaluated uses, available human clinical data, and citations. The committee recommen... | 1.4.3 | 2026-07-23T00:00:00 | 2026-07-26T00:00:00 | https://creativecommons.org/licenses/by/4.0/ | {
"name": "Cora Health",
"url": "https://www.trycora.io",
"contact": "help@trycora.io"
} | The seven peptides the FDA Pharmacy Compounding Advisory Committee (PCAC) evaluated at its July 23-24, 2026 meeting for possible addition to the Section 503A bulk drug substances list: BPC-157, KPV, TB-500, and MOTS-c (July 23), and Emideltide (DSIP), Semax, and Epitalon (July 24). | Row facts trace only to the sources named on that row — the FDA PCAC meeting notice (the authoritative agenda and evaluated uses), FDA pages on the Section 503A bulks list, and contemporaneous reporting from Reuters and RAPS. The FDA staff position is cited as reported by Reuters and RAPS; no FDA staff briefing documen... | All seven vote outcomes are confirmed in the sources reviewed as of the last-verified date. The committee recommended six peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon) and rejected one — Emideltide (DSIP). FDA career staff recommended against listing all seven; the committee voted aga... | None of the peptides in this index is FDA-approved, and none is legal to compound today. They are not therapeutically equivalent to any FDA-approved product. The evidence base for these peptides is thinner than for the compounded GLP-1 medications that licensed providers at Wasef Health, PC prescribe — several have no ... | See an error or an update? Email help@trycora.io — corrections ship with a dataset version bump. | v1.4.3 (2026-07-26): the "It is not legal to compound today." sentence added in v1.4.1 had reached only the MOTS-c note, because the other five recommended notes carried the advisory clause inline rather than by reference; all six recommended notes now share that clause and carry the sentence. Narrowed the methodology ... | [
{
"date": "2026-04-22",
"dateLabel": "April 22, 2026",
"title": "FDA updates the 503A bulk-substances nomination list",
"detail": "Among other changes, the update removed 12 research peptides — including BPC-157, Semax, and TB-500 — from Category 2 of the nomination list. It is a step inside the sam... | [
{
"question": "Did the FDA approve BPC-157, or any of these peptides, in July 2026?",
"shortAnswer": "No.",
"detail": "An FDA advisory committee (PCAC) voted to recommend six of them for the list of bulk substances pharmacies may compound under Section 503A. A recommendation from that committee is non-b... | [
{
"peptide": "BPC-157",
"slug": "bpc-157",
"context": "BPC-157 is one of the seven peptides the FDA's Pharmacy Compounding Advisory Committee evaluated in July 2026. The use the FDA evaluated was ulcerative colitis. The human evidence is thin: FDA staff cited insufficient human data, and the only human ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.